PROTON Holdings

Proton Making H2 From Oilfields, Scaling Way Up

Retrieved on: 
Wednesday, June 9, 2021
Other Energy, Oil, Gas, Alternative energy, Public relations, Investor relations, Energy, Communications, Logistics, Supply chain management, Transport, Chemistry, Physical sciences, Natural sciences, Hydrogen technologies, Hydrogen economy, Emerging technologies, Sustainable technologies, Universal Rocket, Hydrogen, PROTON Holdings, Proton

Last weekend Proton Technologies began loading a trailer with compressed hydrogen from its oilfield.

Key Points: 
  • Last weekend Proton Technologies began loading a trailer with compressed hydrogen from its oilfield.
  • View the full release here: https://www.businesswire.com/news/home/20210609005271/en/
    Proton Technologies Canada Chair and CEO Grant Strem (Photo: Business Wire)
    As we scale up, costs below 25 cents per kg of H2 seem probable, says Chair and CEO, Grant Strem.
  • The process involves injecting oxygen and CO2 into old oilfields like the one Proton purchased out of bankruptcy.
  • We plan to scale-up and proliferate quickly as possible because air pollution is a crisis that Proton Technologies expects to help eradicate while crushing the price of energy and making great returns.

Global Proton Therapy Market Trajectory & Analytics Report 2021: Market to Reach $1.3 Billion by 2027 - U.S. Market is Estimated at $315.2 Million, While China is Forecast to Grow at 2.8% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Radiology, Health, Oncology, Medical devices, Countries, World, Proton, Proton therapy, Asia, PROTON Holdings, China

b'World Current & Future Analysis for Proton Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for Proton Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for Proton Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Single-Room Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Multi-Room Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\n'

Key Points: 
  • b'World Current & Future Analysis for Proton Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for Proton Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for Proton Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Single-Room Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld 15-Year Perspective for Multi-Room Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\n'

Proton Therapy Experts Gather Online for National Proton Conference on April 14th to 16th 2021

Retrieved on: 
Monday, April 5, 2021
Medical physics, Proton, Proton therapy, PROTON Holdings, Companies, Spaceflight, Business law

WASHINGTON, April 5, 2021 /PRNewswire/ --Industry leaders and proton therapy experts from across the globe are registered to attend the National Proton Conference virtually on April 15th and 16th.

Key Points: 
  • WASHINGTON, April 5, 2021 /PRNewswire/ --Industry leaders and proton therapy experts from across the globe are registered to attend the National Proton Conference virtually on April 15th and 16th.
  • It is a cost-effective event for health institutions that are facing economic and administrative burdens from this pandemic," explains Jennifer Maggiore, Executive Director of the National Association for Proton Therapy.
  • Other topics will focus on development of proton centers, construction and design of a proton center, the future of proton therapy and important health policy updates.
  • The National Association for Proton Therapy (NAPT) is an independent nonprofit organization founded in 1990 to educate and increase awareness about the clinical benefits of proton therapy.

NATIONAL ASSOCIATION FOR PROTON THERAPY HONORS YVES JONGEN AS THE 2021 LIFETIME ACHIEVEMENT AWARD RECIPIENT

Retrieved on: 
Friday, February 19, 2021
Health sciences, Medical physics, Proton, Medicine, Applied sciences, Proton therapy, PROTON Holdings, Therapy

Washington, DC, Feb. 19, 2021 (GLOBE NEWSWIRE) -- In recognition of his pioneering work in the field of proton therapy, Yves Jongen, world-renowned researcher and scientist, has been awarded the 2021 National Association for Proton Therapy's Lifetime Achievement Award.

Key Points: 
  • Washington, DC, Feb. 19, 2021 (GLOBE NEWSWIRE) -- In recognition of his pioneering work in the field of proton therapy, Yves Jongen, world-renowned researcher and scientist, has been awarded the 2021 National Association for Proton Therapy's Lifetime Achievement Award.
  • His vision and dedication were rewarded in 1994 when Massachusetts General Hospital commissioned IBA's first cyclotron for proton therapy.
  • Mr. Jongen will share his insight into the next generation for proton therapy during this event.
  • The National Association for Proton Therapy is an independent nonprofit organization founded in 1990 to educate and increase awareness about the clinical benefits of proton therapy.

ProTom International Signed a Strategic Distribution and Licensing Agreement to Distribute with GHGK in China

Retrieved on: 
Monday, January 11, 2021
Health sciences, Applied sciences, Medical physics, Proton, Proton therapy, Branches of science, PROTON Holdings, Radiance, Therapy

Under the Agreement,ProTom has granted an exclusive, long

Key Points: 
  • Under the Agreement,ProTom has granted an exclusive, long
    term license to GHGK as the exclusive distributor of the Radiance 330 system in Mainland China.
  • The Agreement provides fortheexclusive distribution rights to expand tocertain other countries over time.The Agreement also establishes a co-marketing area where ProTom and GHGK will work together to distribute the Radiance 330 in other Asia-Pacific countries.
  • ProTom International Holding Corporation ("ProTom") is a medical technology company focused on proton beam therapy for patients with cancer.
  • GHGK will provide ProTom with full support to develop the market for the Radiance 330 Proton Therapy System in agreed regions.

Global $16.3 Billion PEMFC (Proton Exchange Membrane Fuel Cells) Market to 2027 with Short-term Impact of COVID-19 for 2020 and 2021

Retrieved on: 
Wednesday, December 23, 2020
Energy, Hydrogen technologies, Fuel cells, Proton, Chemistry, Membrane technology, Polymers, Proton-exchange membrane fuel cell, Proton-exchange membrane, PROTON Holdings

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "PEMFC (Proton Exchange Membrane Fuel Cells) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "PEMFC (Proton Exchange Membrane Fuel Cells) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for PEMFC (Proton Exchange Membrane Fuel Cells) estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$16.3 Billion by 2027, growing at a CAGR of 19.8% over the period 2020-2027.
  • The U. S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 19% CAGR
    The PEMFC (Proton Exchange Membrane Fuel Cells) market in the U. S. is estimated at US$1.4 Billion in the year 2020.
  • The 97-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.

Global PEMFC (Proton Exchange Membrane Fuel Cells) Market Trajectory & Analytics Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Other Energy, Energy, Energy, Hydrogen technologies, Fuel cells, Physical sciences, Proton, Membrane technology, Polymers, Proton-exchange membrane fuel cell, Proton-exchange membrane, PROTON Holdings

The "PEMFC (Proton Exchange Membrane Fuel Cells) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PEMFC (Proton Exchange Membrane Fuel Cells) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for PEMFC (Proton Exchange Membrane Fuel Cells) estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$16.3 Billion by 2027, growing at a CAGR of 19.8% over the period 2020-2027.
  • The U. S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 19% CAGR
    The PEMFC (Proton Exchange Membrane Fuel Cells) market in the U. S. is estimated at US$1.4 Billion in the year 2020.
  • The 97-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.

Global Proton Pump Inhibitors Market to Surpass US$ 3.5 Billion by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Friday, October 9, 2020
Biotechnology, Pharmaceutical, Health, Health, Proton pump inhibitors, RTT, Gastroenterology, PROTON Holdings, Heartburn, Pharmaceutical industry, Pfizer, Gastroesophageal reflux disease

According to Coherent Market Insights, the global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% over the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% over the forecast period (2020-2027).
  • Key Trends and Analysis of the Global Proton Pump Inhibitors Market:
    Increasing number of product approvals of proton pump inhibitors by key companies for treatment of heartburn, hyperacidity and GERD is expected to drive growth of the proton pump inhibitors market.
  • The global proton pump inhibitors market is expected to exhibit a CAGR of 4.30% during the forecast period owing to product launches.
  • Key players operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt.

American Shared Hospital Services Reports Second Quarter 2020 Financial Results

Retrieved on: 
Friday, August 14, 2020
Medical physics, Nuclear physics, Finance, Radiation therapy, Physical sciences, Radiobiology, Earnings before interest, taxes, depreciation, and amortization, Fundamental analysis, Profit, Proton therapy, Income, PROTON Holdings

SAN FRANCISCO, CA, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the second quarter ended June 30, 2020.

Key Points: 
  • SAN FRANCISCO, CA, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the second quarter ended June 30, 2020.
  • Total proton therapy fractions in the second quarter decreased 4.1% compared to the second quarter of 2019.The decrease for the second quarter resulted from the impact of the COVID-19 pandemic.
  • Net loss in the second quarter was $483,000 compared to net income of $31,000 for the second quarter of 2019.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,437,000 for the second quarter of 2020, compared to $2,465,000 for the second quarter of 2019.

Legion Healthcare Partners Collaborates with Industry Experts to Provide Proton Therapy Dosimetry Education

Retrieved on: 
Tuesday, June 30, 2020
Medical physics, Academic disciplines, Physical sciences, Health sciences, Radiobiology, Proton, Proton therapy, Radiation therapy, Therapy, PROTON Holdings, Dosimetry, Radiation therapist

Legion Healthcare Partners, working with an international group of dosimetry and physics professionals, has developed the first of its kind structured education program for proton dosimetry.

Key Points: 
  • Legion Healthcare Partners, working with an international group of dosimetry and physics professionals, has developed the first of its kind structured education program for proton dosimetry.
  • The Legion proton therapy education and training program offers 16 CE credit hours and those who enroll in the program can be assured of receiving the highest quality training from prominent proton therapy experts.
  • The program Legion Healthcare Partners and faculty advisors have developed will allow dosimetrists to get their training online from experts in proton therapy," said Cara Sullivan, AAMD President.
  • Legion Healthcare Partners is a group of healthcare executives, clinical advisors and domain experts that provide financing, development, ownership, management services and certified educational programs for radiation oncology with an emphasis on proton therapy.